Centene (CNC) Stock Forecast & Price Target

Centene is viewed positively because its largest Medicaid franchise is entering 2026 with three straight quarters of HBR improvement, constructive state rate dialogue, and 1Q26 adjusted EPS of $3.37 that helped lift full-year guidance to >$3.40 after a challenging 2025. Its Marketplace book was fully repriced with mid-30s% increases, membership of 3.58 million, and a shift from a net risk-adjustment payable to a slight receivable, creating meaningful upside if margins move toward 4% rather than the guided ~3%. The company also has long-duration support from Medicare recovery, 8.78 million PDP members, and structurally advantaged D-SNP alignment across its 30-state Medicaid footprint, which reinforces multi-year earnings restoration.

Centene is facing a negative fundamental setup because recent earnings recovery is coming off a severe 2025 reset, when adjusted EPS fell about $5 below the original >$7.25 guide, the company booked a $6.7B goodwill impairment in 3Q25, and management has still not re-anchored its long-term earnings framework. The business also faces structural pressure from the OBBBA, which the CBO says will cut federal Medicaid spending by about $910B over the next decade and could leave roughly 4.8MM fewer people covered by 2034, while Centene expects Medicaid membership to decline about 6% from year-end 2025 to year-end 2026 amid rate/acuity mismatch and elevated behavioral health costs. Marketplace economics are also fragile after enhanced subsidies expired at year-end 2025, with 1Q Marketplace membership down about 35.4% since YE25 to roughly 3.58MM and 2025 pre-tax margin near -1%, underscoring persistent volatility across Medicaid, Commercial, and Medicare.